Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.59

-0.9%

Oct 30 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1385)	10/9/2002 8:05:57 AM
From: Icebrg	Read Replies (2) of 1475

MedImmune at UBS Warburg (Jim Young @ 19:25) Siplizumab or MEDI507 our anti-CD2 monoclonal antibody was originally developed for prevention of T-Cell mediated diseases such as psoriasis. We recently completed three large phase II studies. Those are being analyzed literally as we speak back in Gaithersburg. We hope that results from those initial phase IIs will enable us to know whether or not we have a product to proceed with and if so have a design pivotal studies and hopefully we will have an opportunity to get into those next year. In addition if those phase II studies are encouraging we hope to begin additional studies in psoriatic arthritis and T-Cell lymphoma patients later this year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next